Kienan I Savage
Overview
Explore the profile of Kienan I Savage including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1058
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Griffin D, Carson R, Moss D, Sessler T, Lavin D, Tiwari V, et al.
Mol Cancer Res
. 2024 Jul;
22(12):1088-1101.
PMID: 39083088
Patients with class I V600EBRAF-mutant (MT) colorectal cancer exhibit a poor prognosis, and their response to combined anti-BRAF/EGFR inhibition remains limited. An unmet need exits for further understanding the biology...
2.
Bradley L, Savage K
DNA Repair (Amst)
. 2023 Oct;
131:103581.
PMID: 37832251
Cells possess an inherent and evolutionarily conserved ability to detect and respond to the presence of foreign and pathological 'self' nucleic acids. The result is the stimulation of innate immune...
3.
Barros E, McIntosh S, Savage K
DNA Repair (Amst)
. 2022 Oct;
120:103409.
PMID: 36308822
Genomic instability is a hallmark of tumourigenesis, influencing tumour development and progression. In particular, defects in the DNA damage response (DDR) have been extensively investigated and are known to shape...
4.
Lappin K, Barros E, Jhujh S, Irwin G, McMillan H, Liberante F, et al.
Cancer Res
. 2022 Jan;
82(5):819-830.
PMID: 35027467
Significance: The cancer-associated SF3B1K700E mutation induces DNA damage via generation of genotoxic R-loops and stalled replication forks, defective homologous recombination, and increased replication fork degradation, which can be targeted with...
5.
Parkes E, Savage K, Lioe T, Boyd C, Halliday S, Walker S, et al.
Br J Cancer
. 2021 Nov;
126(2):247-258.
PMID: 34728791
Background: The DNA-damage immune-response (DDIR) signature is an immune-driven gene expression signature retrospectively validated as predicting response to anthracycline-based therapy. This feasibility study prospectively evaluates the use of this assay...
6.
Suraweera A, Gandhi N, Beard S, Burgess J, Croft L, Bolderson E, et al.
Commun Biol
. 2021 Apr;
4(1):484.
PMID: 33875784
Genomic stability is critical for normal cellular function and its deregulation is a universal hallmark of cancer. Here we outline a previously undescribed role of COMMD4 in maintaining genomic stability,...
7.
Ali R, McIntosh S, Savage K
Genes Chromosomes Cancer
. 2020 Nov;
60(5):358-372.
PMID: 33247475
An underlying cause of breast cancers has been largely attributed to defects in the DNA damage response (DDR) pathway. In particular, the homologous recombination (HR) pathway repairs double-stranded breaks (DSBs)...
8.
Smith J, Lappin K, Craig S, Liberante F, Crean C, McDade S, et al.
J Transl Med
. 2020 Sep;
18(1):339.
PMID: 32883299
Background: The cohesin complex plays a major role in folding the human genome into 3D structural domains. Mutations in members of the cohesin complex are known early drivers of myelodysplastic...
9.
McCrorie A, Ashfield S, Begley A, Mcilmunn C, Morrison P, Boyd C, et al.
J Pathol Clin Res
. 2020 Feb;
6(2):146-153.
PMID: 32022473
Multifocal (MF)/multicentric (MC) breast cancer is generally considered to be where two or more breast tumours are present within the same breast, and is seen in ~10% of breast cancer...
10.
Liberante F, Lappin K, Barros E, Vohhodina J, Grebien F, Savage K, et al.
Sci Rep
. 2019 Feb;
9(1):2678.
PMID: 30804405
Myelodysplastic syndromes (MDS) are haematopoietic malignancies that are characterised by a heterogeneous clinical course. In recent years, sequencing efforts have uncovered recurrent somatic mutations within RNA splicing factors, including SF3B1,...